Chronic obstructive pulmonary disease (COPD)

May 23, 2016May 23, 2016

Acute COPD Improved by Inhibitor, Approved Bronchodilators

COPD, News

Verona Pharma has announced positive results from the Phase 2a trial evaluating a phosphodiesterase (PDE) 3/4 inhibitor, RPL554, in patients with chronic obstructive pulmonary disorder (COPD). COPD is a progressive ... Read more

May 20, 2016May 20, 2016

Positive Data on COPD Therapy Breo Ellipta SUMMIT Study Presented by GSK

COPD, News

GlaxoSmithKline (GSK) and Innoviva recently presented positive results from two analyses of the SUMMIT trial, which investigated the efficacy and safety of Breo Ellipta (fluticasone furoate/vilanterol, or FF/VI 100/25 mcg) in patients with chronic obstructive pulmonary disease (COPD) ... Read more

May 19, 2016May 19, 2016

Phase 3 Drug Improves Lung Function for COPD Patients with Symptoms After Tiotropium

COPD, News

A new phase 3 clinical study conducted by GSK and Innoviva, Inc. shows that Anoro Ellipta significantly improves lung function in people with COPD, compared to another drug called tiotropium.

May 3, 2016May 4, 2016

FDA Approves COPD Treatment Bevespi Aerosphere, a Long-acting Dual Bronchodilator

Chronic Bronchitis, COPD, Emphysema, News

The U.S. FDA has approval AstraZeneca’s Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) for long-term maintenance treatment of airflow obstruction in patients suffering from chronic obstructive pulmonary disease (COPD), including emphysema and/or chronic bronchitis. ... Read more

April 7, 2016April 7, 2016

Study of Roflumilast for COPD Confirms Benefits as Alternative Therapy

COPD, News

Researchers at Sichuan University in China conducted a study to clarify the controversial therapeutic effects of roflumilast in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). The team found that roflumilast led ... Read more

March 31, 2016May 13, 2016

Stiolto Respimat for COPD Granted FDA’s Supplemental NDA Approval

Chronic Bronchitis, COPD, Emphysema, News

The FDA has approved a supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s Stiolto Respimat, which, according to the company, adds data to the product’s label demonstrating improvements in health and quality ... Read more

March 29, 2016May 13, 2016

Digital Aid to Manage COPD and Asthma Being Made Available to RESPIMAT Inhaler Users

Asthma, COPD, News

Propeller Health and Boehringer Ingelheim Pharmaceuticals recently announced a commercial collaboration, based on joint use of the companies’ health tools and services, in an effort to help people better manage long-term lung conditions like asthma and ... Read more

February 10, 2016February 10, 2016

Lung Function in COPD Patients Shows Promise With STIOLTO RESPIMAT Inhalation Spray

COPD, News

Boehringer Ingelheim Pharmaceuticals announced the publication of promising new data regarding its inhalation spray, STIOLTO RESPIMAT, in the improvement of lung function when compared to therapy with an European formulation combining ... Read more

January 25, 2016January 25, 2016

In COPD Study, Women Found to Be at Much Higher Risk for Disease

COPD, News

In a new study, researchers at Lund University in Sweden suggested that females could be an independent risk factor for chronic obstructive pulmonary disease (COPD), with the risk of developing the disease possibly ... Read more

December 18, 2015December 19, 2015

Bacterial Infections Tied to COPD Flares May Be Determined Through Comorbidities

COPD, News

A new study found that the etiology of bacterial infections in acute exacerbations of chronic obstructive pulmonary disease could be determined through their associated comorbidities, a finding with relevance for clinical practice. ... Read more